Curaleaf Holdings (CURLF) Shares Outstanding (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Shares Outstanding (Entity) of $775.4 million for Q1 2026, up 4.1% year-on-year from $744.9 million in Q1 2025, and up 1.75% on a QoQ basis from $762.1 million in Q4 2025.
Curaleaf Holdings (CURLF) Shares Outstanding (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Shares Outstanding (Entity) for 8 consecutive years, with $775.4 million the latest figure, recorded in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 4.1% year-over-year to $775.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $775.4 million (up 4.1% YoY) and the FY2025 annual result came in at $762.1 million, up 2.87% from the prior year.
- Shares Outstanding (Entity) improved to $775.4 million in Q1 2026 per CURLF's latest filing, from $762.1 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for CURLF reached as high as $775.4 million in Q1 2026 and fell as low as $708.9 million in Q1 2022.
- A 5-year average of $738.8 million and a median of $739.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2025 — Shares Outstanding (Entity) rose 1.19% — and 2026, when it advanced 4.1%.
- Year by year, Shares Outstanding (Entity) stood at $711.2 million in 2022, then gained by 1.82% to $724.1 million in 2023, then gained by 2.31% to $740.8 million in 2024, then climbed by 2.87% to $762.1 million in 2025, then grew by 1.75% to $775.4 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $775.4 million, $762.1 million, and $758.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 8.98 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.16 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 422.10 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 455,871.00 |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 100.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 497.70 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | 775.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 775.43 Mn |
| Dec 31, 2025 | 762.09 Mn |
| Sep 30, 2025 | 758.81 Mn |
| Jun 30, 2025 | 755.74 Mn |
| Mar 31, 2025 | 744.90 Mn |
| Dec 31, 2024 | 740.83 Mn |
| Sep 30, 2024 | 742.54 Mn |
| Jun 30, 2024 | 738.47 Mn |
| Mar 31, 2024 | 736.15 Mn |
| Dec 31, 2023 | 724.12 Mn |
| Sep 30, 2023 | 725.32 Mn |
| Jun 30, 2023 | 719.02 Mn |
| Mar 31, 2023 | 718.12 Mn |
| Dec 31, 2022 | 711.16 Mn |
| Sep 30, 2022 | 709.80 Mn |
| Jun 30, 2022 | 709.97 Mn |
| Mar 31, 2022 | 708.90 Mn |
| Dec 31, 2021 | 698.76 Mn |
| Sep 30, 2021 | 703.55 Mn |
| Jun 30, 2021 | 701.67 Mn |